Detalles de la búsqueda
1.
Regulatory myeloid cells paralyze T cells through cell-cell transfer of the metabolite methylglyoxal.
Nat Immunol;
21(5): 555-566, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32327756
2.
Effect of abrocitinib on skin biomarkers in patients with moderate-to-severe atopic dermatitis.
Allergy;
79(5): 1258-1270, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38108208
3.
Baricitinib treatment rapidly improves the four signs of atopic dermatitis assessed by Eczema Area and Severity Index (EASI) clinical subscores.
J Eur Acad Dermatol Venereol;
38(4): 695-702, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38041556
4.
Real-world clinical, psychosocial and economic burden of atopic dermatitis: Results from a multicountry study.
J Eur Acad Dermatol Venereol;
38(2): 340-353, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37669868
5.
The neglected twin: Nummular eczema is a variant of atopic dermatitis with codominant TH2/TH17 immune response.
J Allergy Clin Immunol;
152(2): 408-419, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37119871
6.
Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial.
Lancet;
400(10348): 273-282, 2022 07 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-35871814
7.
Matrix metalloproteinases in coronary artery disease and myocardial infarction.
Basic Res Cardiol;
118(1): 18, 2023 05 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37160529
8.
Biomarkers associated with the development of comorbidities in patients with atopic dermatitis: A systematic review.
Allergy;
78(1): 84-120, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36366871
9.
The integration of large-scale public data and network analysis uncovers molecular characteristics of psoriasis.
Hum Genomics;
16(1): 62, 2022 11 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-36437479
10.
Autosomal dominant inheritance with sex-limited manifestation: An unusual mode of transmission in humans and animals.
Am J Med Genet A;
191(3): 684-689, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36538935
11.
Guselkumab demonstrates long-term efficacy and maintenance of treatment response post-withdrawal in systemic-treatment naïve patients and non-responders to fumaric acid esters: Results from parts II and III of a randomised, active-comparator-controlled phase IIIb trial (POLARIS).
Br J Dermatol;
2023 Dec 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-38133615
12.
Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial.
J Am Acad Dermatol;
89(3): 486-495, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37182701
13.
Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up).
J Am Acad Dermatol;
89(3): 478-485, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37230366
14.
Histology-based classifier to distinguish early mycosis fungoides from atopic dermatitis.
J Eur Acad Dermatol Venereol;
37(11): 2284-2292, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37422709
15.
Eczematized psoriasis - a frequent but often neglected variant of plaque psoriasis.
J Dtsch Dermatol Ges;
21(5): 445-453, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36772926
16.
Status quo and future perspectives of molecular diagnostics in dermatology.
J Dtsch Dermatol Ges;
21(4): 415-418, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36892267
17.
EAACI Biologicals Guidelines-Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old.
Allergy;
77(1): 17-38, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34324716
18.
Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4).
Br J Dermatol;
187(3): 338-352, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35484697
19.
Biomarkers of systemic treatment response in people with psoriasis: a scoping review.
Br J Dermatol;
187(4): 494-506, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35606928
20.
Biomarkers of disease progression in people with psoriasis: a scoping review.
Br J Dermatol;
187(4): 481-493, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35482474